SPART

Across TCGA pan-cancer cohorts, SPART Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPART data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SPART Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SPART expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, LUSC, and ESCA are the cancer types where SPART Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.931	0.434	.015	24	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	15	view →
ESCA	OS	Median	II,III,IV	0.376	0.710	.014	6	view →
STAD	DFS	Median	II,III,IV	0.866	0.323	.035	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPART–UCEC (DFS)

Open the UCEC breakdown →